Platelet disorders in children: A diagnostic approach

The investigation of children with suspected inherited platelet disorders is challenging. The causes of mucocutaneous bleeding are many, and specialized testing for platelet disorders can be difficult to access or interpret. An algorithm developed for the investigation of suspected platelet disorders provides a sequential approach to evaluating both platelet function abnormalities and thrombocytopenia. Investigation begins with a clinical evaluation and laboratory testing that is generally available, including platelet counting, peripheral blood cell morphology, and aggregometry. Based on results of initial investigations, the algorithm recommends specialized testing for specific diagnoses, including flow cytometry, immunofluorescence microscopy, electron microscopy, and mutational analysis. Pediatr Blood Cancer 2011;56:975–983. © 2011 Wiley‐Liss, Inc.

[1]  P. Nurden,et al.  Diagnostic Assessment of Platelet Function , 2013 .

[2]  Nancy F. Hansen,et al.  Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p. , 2010, Blood.

[3]  S. Israels,et al.  Inherited disorders of platelet function and challenges to diagnosis of mucocutaneous bleeding , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  V. Blanchette,et al.  Use of a quantitative pediatric bleeding questionnaire to assess mucocutaneous bleeding symptoms in children with a platelet function disorder , 2010, Journal of thrombosis and haemostasis : JTH.

[5]  G. Lippi,et al.  Contemporary platelet function testing , 2010, Clinical chemistry and laboratory medicine.

[6]  G. D. Angelis,et al.  Multiplate® Whole Blood Impedance Point of Care Aggregometry: Preliminary Reference Values in Healthy Infants, Children and Adolescents , 2010, Klinische Padiatrie.

[7]  V. Blanchette,et al.  Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire , 2010, Journal of thrombosis and haemostasis : JTH.

[8]  A. Goodeve.  The genetic basis of von Willebrand disease. , 2010, Blood reviews.

[9]  R. Knöfler,et al.  Inherited Disorders of Platelet Function in Pediatric Clinical Practice: A Diagnostic Challenge , 2010, Klinische Padiatrie.

[10]  P. Noris,et al.  Heavy chain myosin 9-related disease (MYH9-RD): Neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder , 2010, Thrombosis and Haemostasis.

[11]  A. Paterson,et al.  Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene. , 2010, Blood.

[12]  Drew Provan,et al.  International consensus report on the investigation and management of primary immune thrombocytopenia. , 2010, Blood.

[13]  A. Tosetto,et al.  Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire , 2009, Journal of thrombosis and haemostasis : JTH.

[14]  E. Duncan,et al.  Methodology and outcomes of platelet aggregation testing in Australia, New Zealand and the Asia‐Pacific region: results of a survey from the Royal College of Pathologists of Australasia Haematology Quality Assurance Program , 2009, International journal of laboratory hematology.

[15]  A. Michelson,et al.  Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH , 2009, Journal of thrombosis and haemostasis : JTH.

[16]  S. Mundell,et al.  Identification and characterization of a novel P2Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. , 2009, Blood.

[17]  M. Poon,et al.  The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation. , 2009, Blood.

[18]  P. Nurden.  The VWD2B saga continues to Montreal. , 2009, Blood.

[19]  A. Geddis.  Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii. , 2009, Hematology/oncology clinics of North America.

[20]  M. Cattaneo.  Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. , 2009, Seminars in thrombosis and hemostasis.

[21]  S. Israels.  Diagnostic evaluation of platelet function disorders in neonates and children: an update. , 2009, Seminars in thrombosis and hemostasis.

[22]  P. Nurden,et al.  Genetic testing in the diagnostic evaluation of inherited platelet disorders. , 2009, Seminars in thrombosis and hemostasis.

[23]  Paul J. Harrison,et al.  Screening tests of platelet function: update on their appropriate uses for diagnostic testing. , 2009, Seminars in thrombosis and hemostasis.

[24]  A. Greinacher,et al.  MYH9-related platelet disorders. , 2009, Seminars in thrombosis and hemostasis.

[25]  E. Cramer-Bordé,et al.  Role of Platelet Electron Microscopy in the Diagnosis of Platelet Disorders , 2009, Seminars in thrombosis and hemostasis.

[26]  G. Fritsma,et al.  Whole blood platelet aggregometry and platelet function testing. , 2009, Seminars in thrombosis and hemostasis.

[27]  A. Paterson,et al.  Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes. , 2009, Blood.

[28]  M. Diamandis,et al.  Increased Expression of Urokinase Plasminogen Activator in Quebec , 2022 .

[29]  P. James,et al.  Generation and validation of the Condensed MCMDM‐1VWD Bleeding Questionnaire for von Willebrand disease , 2008, Journal of thrombosis and haemostasis : JTH.

[30]  W. Gahl,et al.  Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. , 2008, Annual review of genomics and human genetics.

[31]  S. Kitchen,et al.  Platelet function testing: practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006 , 2008, Journal of Clinical Pathology.

[32]  C. Hayward.  Diagnostic approach to platelet function disorders. , 2008, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[33]  E. Favaloro,et al.  Phenotypic Identification of Platelet-Type von Willebrand Disease and Its Discrimination from Type 2B von Willebrand Disease: A Question of 2B or Not 2B? A Story of Nonidentical Twins? Or Two Sides of a Multidenominational or Multifaceted Primary-Hemostasis Coin? , 2008, Seminars in thrombosis and hemostasis.

[34]  P. Nurden,et al.  Congenital disorders associated with platelet dysfunctions , 2008, Thrombosis and Haemostasis.

[35]  M. Bonduel,et al.  Platelet aggregation and adenosine triphosphate release values in children and adults , 2007, Journal of thrombosis and haemostasis : JTH.

[36]  R. Bamberg,et al.  Comparison of Two Platelet Count Estimation Methodologies for Peripheral Blood Smears , 2007, American Society for Clinical Laboratory Science.

[37]  W. Muntean,et al.  PFA-100 closure times in preoperative screening in 500 pediatric patients , 2007, Thrombosis and Haemostasis.

[38]  O. Panes,et al.  High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. , 2007, Haematologica.

[39]  W. Eberl,et al.  Erste Ergebnisse der THROMKID-Studie , 2007, Hämostaseologie.

[40]  Peter Hellstern,et al.  Variables influencing Multiplate™ whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals , 2007, Platelets.

[41]  S. Watson,et al.  A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO , 2006, British journal of haematology.

[42]  M. Cattaneo,et al.  Congenital platelet disorders: overview of their mechanisms, diagnostic evaluation and treatment , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[43]  K. Chorneyko,et al.  Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis , 2006, Journal of thrombosis and haemostasis : JTH.

[44]  A. Tosetto,et al.  A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD) , 2006, Journal of thrombosis and haemostasis : JTH.

[45]  P. Noris,et al.  von Willebrand disease type 2B must be always considered in the differential diagnosis of genetic thrombocytopenias with giant platelets , 2006, Platelets.

[46]  D. Chitayat,et al.  Requirement of VPS33B, a member of the Sec1/Munc18 protein family, in megakaryocyte and platelet alpha-granule biogenesis. , 2005, Blood.

[47]  A. Tosetto,et al.  The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study , 2005, Journal of thrombosis and haemostasis : JTH.

[48]  M. Kelley,et al.  Genotype–phenotype correlation in MYH9‐related thrombocytopenia , 2005, British journal of haematology.

[49]  Paul J. Harrison.  The role of PFA‐100® testing in the investigation and management of haemostatic defects in children and adults , 2005, British journal of haematology.

[50]  W. Nichols,et al.  Variability in clinical laboratory practice in testing for disorders of platelet function , 2005, Thrombosis and Haemostasis.

[51]  M. Carlo L. Balduini,et al.  Inherited Thrombocytopenias: Molecular Mechanisms , 2022 .

[52]  W. Abdullah.  Pediatr Blood Cancer , 2004 .

[53]  F. Adam,et al.  Bleeding risks associated with inheritance of the Quebec platelet disorder. , 2004, Blood.

[54]  O. Panes,et al.  Template bleeding time and PFA‐100® have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients , 2004, Journal of thrombosis and haemostasis : JTH.

[55]  M. Cattaneo.  Are the bleeding time and PFA‐100® useful in the initial screening of patients with mucocutaneous bleedings of hereditary nature? , 2004, Journal of thrombosis and haemostasis : JTH.

[56]  D. Eslin,et al.  Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. , 2003, Blood.

[57]  G. Rivard,et al.  Intracellular activation of the fibrinolytic cascade in the Quebec Platelet Disorder , 2003, Thrombosis and Haemostasis.

[58]  R. Schwartz,et al.  Platelet functional defects in women with unexplained menorrhagia , 2003, Journal of thrombosis and haemostasis : JTH.

[59]  T. Podor,et al.  Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. , 2001, Blood.

[60]  Shapiro,et al.  Platelet function disorders , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[61]  S. Orkin,et al.  Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1 , 2000, Nature Genetics.

[62]  J. White,et al.  Giant platelet disorders in African-American children misdiagnosed as idiopathic thrombocytopenic purpura. , 1999, Journal of pediatric hematology/oncology.

[63]  G. Rivard,et al.  Studies of a second family with the Quebec platelet disorder: evidence that the degradation of the alpha-granule membrane and its soluble contents are not secondary to a defect in targeting proteins to alpha-granules. , 1997, Blood.

[64]  J. Smith.  Factor XI deficiency and its management , 1996, Haemophilia : the official journal of the World Federation of Hemophilia.

[65]  J. Kelton,et al.  An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect. , 1996, Blood.

[66]  K. Mann,et al.  Factor V Quebec revisited. , 1996, Blood.

[67]  J. Okita,et al.  Montreal platelet syndrome: a defect in calcium-activated neutral proteinase (calpain). , 1989, Blood.

[68]  K. Mann,et al.  Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency. , 1984, The Journal of clinical investigation.

[69]  J. White,et al.  Spontaneous Platelet Aggregation In A Hereditary ‘giant’ Platelet Syndrome (MPS) , 1984, Thrombosis and Haemostasis.

[70]  S. Mundell,et al.  Phenotypic approaches to gene mapping in platelet function disorders , 2010, Hämostaseologie.

[71]  H. Ochs,et al.  Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[72]  P. Nurden,et al.  The gray platelet syndrome: clinical spectrum of the disease. , 2007, Blood reviews.

[73]  M. Furman,et al.  CHAPTER 30 – Flow Cytometry , 2007 .

[74]  D. Chitayat,et al.  Requirement of VPS 33 B , a member of the Sec 1 / Munc 18 protein family , in megakaryocyte and platelet-granule biogenesis , 2005 .

[75]  J. White.  Electron microscopy methods for studying platelet structure and function. , 2004, Methods in molecular biology.

[76]  P. Noris,et al.  Application of a diagnostic algorithm for inherited thrombocytopenias to 46 consecutive patients. , 2004, Haematologica.

[77]  F. Fabris,et al.  Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine. , 2003, Haematologica.

[78]  M. Ballmaier,et al.  c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. , 2001, Blood.

[79]  D. Grasso,et al.  Flow cytometry. , 1998, Methods in molecular medicine.

[80]  D. Ginsburg,et al.  Von Willebrand disease. , 2008, Pediatric clinics of North America.

[81]  M. Frojmovic,et al.  Shape-changing agents produce abnormally large platelets in a hereditary "giant platelets syndrome (MPS)". , 1979, The Journal of laboratory and clinical medicine.